J Clin Oncol 2003, 21:2697–2702.PubMedCrossRef 6. Sakaeda T, Yamamori

M, Kuwahara A, Nishiguchi K: Pharmacokinetics and pharmacogenomics in esophageal cancer chemoradiotherapy. Adv Drug Deliv Rev 2009, 61:388–401.PubMedCrossRef 7. Miki I, Tamura T, Nakamura T, Makimoto H, Hamana N, Uchiyama H, Pexidartinib concentration Shirasaka D, Morita Y, Yamada H, Aoyama N, Sakaeda T, Okumura K, Kasuga M: Circadian variability of pharmacokinetics of 5-fluorouracil and CLOCK T3111C genetic polymorphism in patients with esophageal carcinoma. Ther Drug Monit 2005, 27:369–374.PubMedCrossRef 8. Okuno T, Tamura T, Yamamori M, Chayahara N, Yamada T, Miki I, Okamura N, Kadowaki Y, Shirasaka D, Aoyama N, Nakamura T, Okumura K, Azuma T, Kasuga M, Sakaeda T: Favorable genetic polymorphisms predictive of clinical outcome of chemoradiotherapy for Stage II/III esophageal squamous cell carcinoma in Japanese. Am J Clin Oncol 2007,

30:252–257.PubMedCrossRef 9. Sakaeda T, Yamamori M, Kuwahara A, Hiroe S, Nakamura T, Okumura K, Okuno T, Miki I, Chayahara N, Okamura N, Tamura T: VEGF G-1154A is predictive of severe acute toxicities during chemoradiotherapy for esophageal squamous cell carcinoma in Japanese patients. Ther Drug Monit 2008, 30:497–503.PubMed 10. Cucchiara S, Latiano A, Palmieri O, Canani RB, D’Incà R, Guariso G, Vieni G, De Venuto D, Riegler G, De’Angelis GL, Guagnozzi D, Bascietto C, Miele E, Valvano MR, Bossa F, Annese V, Italian Society of Pediatric Gastroenterology

and Nutrition: Polymorphisms of tumor necrosis factor-alpha but not MDR1 influence response to medical therapy selleck chemicals llc in pediatric-onset inflammatory acetylcholine bowel disease. J Pediatr Gastroenterol Nutr 2007, 44:171–179.PubMedCrossRef 11. Sashio H, Tamura K, Ito R, Yamamoto Y, Bamba H, Kosaka T, Fukui S, Sawada K, Fukuda Y, Tamura K, Satomi M, Shimoyama T, Furuyama J: Polymorphisms of the TNF gene and the TNF receptor superfamily member 1B gene are associated with susceptibility to ulcerative colitis and EPZ015938 Crohn’s disease, respectively. Immunogenetics 2002, 53:1020–1027.PubMedCrossRef 12. Sýkora J, Subrt I, Dìdek P, Siala K, Schwarz J, Machalová V, Varvarovská J, Pazdiora P, Pozler O, Stozický F: Cytokine tumor necrosis factor-alpha A promoter gene polymorphism at position -308 G>A and pediatric inflammatory bowel disease: implications in ulcerative colitis and Crohn’s disease. J Pediatr Gastroenterol Nutr 2006, 42:479–487.PubMedCrossRef 13. Waschke KA, Villani AC, Vermeire S, Dufresne L, Chen TC, Bitton A, Cohen A, Thomson AB, Wild GE: Tumor necrosis factor receptor gene polymorphisms in Crohn’s disease: association with clinical phenotypes. Am J Gastroenterol 2005, 100:1126–1133.PubMedCrossRef 14. Lu Z, Chen L, Li H, Zhao Y, Lin L: Effect of the polymorphism of tumor necrosis factor-alpha-308 G/A gene promoter on the susceptibility to ulcerative colitis: a meta-analysis. Digestion 2008, 78:44–51.